Europe Hip Replacement Devices Market

Europe Hip Replacement Devices Market Size

The europe hip replacement devices market size was valued at USD 1.72 billion in 2025, is expected to have a 3.2% CAGR from 2026 to 2034, and be worth USD 2.29 billion by 2034 from USD 1.78 billion in 2026.

Hip Replacement Devices refer to orthopaedic implants and instrumentation systems used in total or partial hip arthroplasty to restore joint function compromised by osteoarthritis, trauma, or degenerative conditions. These devices primarily include femoral stems, acetabular cups, and modular heads fabricated from biocompatible materials such as titanium, cobalt chromium alloys, and highly cross-linked polyethylene. As of 2025, a large number of hip replacement procedures are performed annually across the European Union, according to Eurostat healthcare statistics. The ageing demographic structure significantly underpins surgical demand, with individuals aged 65 and older constituting nearly 21 percent of the EU population, as per the European Commission’s 2024 demographic outlook. Furthermore, the rising prevalence of obesity, a key risk factor for early onset osteoarthritis, exacerbates joint deterioration with rising prevalence of obesity exacerbates joint deterioration, according to the World Health Organization’s European Regional Office. National healthcare systems in countries like Germany, Sweden, and the Netherlands maintain robust orthopaedic surgical capacities yet face mounting pressure to reduce waiting times, which averaged several weeks for elective joint replacements in 2024. This confluence of demographic, clinical, and systemic factors frames the operational context for hip implant innovation and adoption across Europe.

MARKET DRIVERS

Accelerated Ageing Population Fuels Surgical Demand for Joint Restoration

The region’s progressive demographic ageing directly correlates with increased incidence of degenerative joint diseases necessitating hip arthroplasty, and this propels the growth of the European hip replacement devices market. The European Union's population is getting older, with a growing segment of citizens reaching the age of 65 and beyond, according to sources. This cohort experiences a markedly higher prevalence of hip osteoarthritis, with a notable number of older Europeans showing signs of hip joint wear and tear, as per research. Many hip replacement operations are performed in Germany each year, which indicates a significant need for this type of surgery. Public healthcare frameworks in Nordic countries further prioritise mobility-preserving procedures. Patients increasingly seek durable solutions that support active lifestyles into advanced age, given that life expectancy continues to rise. This sustained clinical need creates a structural and non-cyclical driver for implant utilisation across both public and private orthopaedic care settings.

Advancements in Implant Longevity and Minimally Invasive Surgical Techniques Enhance Patient Outcomes

Technological refinements in bearing surfaces and fixation methods are fuelling the expansion of the European hip replacement devices market. These advancements have substantially extended the functional lifespan of hip replacements. Modern implants utilizing ceramic-on-ceramic or highly cross-linked polyethylene (HXLPE) articulations demonstrate low wear rates, typically below 0.05 millimetres per year, as per studies. Concurrently, the adoption of minimally invasive anterior and lateral approaches has reduced average hospital stays to under a few days in countries. These procedures result in faster rehabilitation. Minimally invasive approaches and enhanced recovery after surgery (ERAS) protocols have reduced average hospital stays, which often results in patients being discharged within 1-3 days in many countries. Enhanced recovery protocols integrated with robotic-assisted implant placement further improve precision and reduce dislocation risks. Such innovations not only elevate patient satisfaction but also align with national healthcare objectives to lower complication-related readmissions and optimise operating theatre throughput.

MARKET RESTRAINTS

Stringent Regulatory Pathways Under EU Medical Device Regulation Delay Product Commercialisation

The enforcement of Regulation EU 2017 745 has significantly intensified clinical evidence and post-market surveillance requirements for orthopaedic implants, which further boosts the expansion of the European hip replacement devices market. Manufacturers must now demonstrate comprehensive biocompatibility data, real-world performance metrics, and risk management documentation before CE certification can be granted. According to sources, the average approval timeline for Class III devices such as hip replacements has extended to several months. This delay impedes the timely introduction of next-generation designs, including 3D printed porous stems and antimicrobial-coated components. Moreover, notified bodies face a backlog of pending conformity assessments. Small and medium-sized orthopaedic firms lacking dedicated regulatory teams are disproportionately affected, with several delaying European launches to prioritise less stringent regions. Consequently, innovation diffusion across the EU lags behind the United States, where the FDA’s breakthrough device pathway facilitates faster access to novel joint solutions.

Persistent Pressure on Public Healthcare Budgets Constricts Procurement Flexibility

National health systems in the region face escalating fiscal constraints, which hamper the expansion of the European hip replacement devices market. This is driven by ageing populations and rising treatment costs. In addition, healthcare expenditure accounted for a portion of GDP in the EU, yet orthopaedic device budgets remain tightly controlled, as per studies. Countries like Italy and Spain enforce mandatory tendering processes that prioritise the lowest cost over clinical differentiation, leading to the commoditisation of implant selection. These financial levers reduce hospitals’ autonomy to select technologically advanced devices even when long-term cost effectiveness is demonstrated. As a result, surgeons often compromise on implant features to comply with procurement frameworks, thereby dampening market receptivity to innovation despite strong clinical rationale.

MARKET OPPORTUNITIES

Integration of Patient-Specific Implants and 3D Printing Technologies Expands Customisation Potential. Al.

Additive manufacturing enables the production of patient-matched hip implants with anatomically precise geometries and porous osseointegration surfaces, which are setting up new opportunities for the growth of the European hip replacement devices market. Hospitals in parts of Europe are increasingly integrating 3D printed titanium implants into routine surgical procedures, according to research. These custom devices reduce operative time and improve bone ingrowth. There is a clear trend toward significant financial investment from the European Union in research and projects that advance the field of digital orthopaedics. Regulatory pathways for such bespoke implants are also being streamlined. The feasibility of routine patient-specific hip arthroplasty increases with advancements in imaging resolution and surgical navigation accuracy, particularly for complex dysplastic or post-traumatic cases where standard implants yield suboptimal results. This technological convergence positions customisation as a high-value growth vector aligned with precision medicine paradigms.

Expansion of Ambulatory Orthopaedic Centres Facilitates Same-Day Hip Replacement Adoption

The shift toward outpatient joint replacement is gaining momentum across Western and Northern Europe, which provides fresh prospects for the expansion of the European hip replacement devices market. This is driven by enhanced anaesthesia protocols and accelerated rehabilitation pathways. These centres prioritise implants with proven short-term stability and low dislocation rates, such as dual mobility or short stem designs. Device manufacturers are responding by developing pre-sterilised single-use instrument kits and simplified implant systems that reduce logistical complexity in non-hospital environments. This structural shift not only reduces systemic costs but also opens new commercial channels for agile and modular implant portfolios.

MARKET CHALLENGES

High Revision Burden Due to Implant Wear and Periprosthetic Joint Infection Complicates Long-Term Outcomes

Implant wear and periprosthetic joint infection led to a high revision burden, which complicates long-term outcomes for patients and constrains the growth of the European hip replacement devices market. Despite technological advances, a notable proportion of hip replacements require revision primarily due to aseptic loosening or infection. The Nordic Arthroplasty Register Association reports that the 15-year cumulative revision rates for all total hip arthroplasties vary by country, with rates for Sweden, Norway, and Denmark ranging from approximately 12% to 14% (meaning 15-year survival rates are between 86% and 88%, respectively). Periprosthetic joint infection is an uncommon event following surgery, affecting a very small proportion of individuals who undergo the procedure, according to studies. In Germany, a significant number of revision hip surgeries occur each year, reflecting ongoing needs for follow-up procedures. These reoperations require substantially more resources than the initial surgeries, leading to significantly higher average costs. Moreover, emerging evidence suggests that metal-on-metal bearings, though largely phased out, continue to contribute to late adverse reactions. The UK continues to monitor thousands of individuals who have metal-on-metal hip implants to track potential long-term issues. This persistent revision burden not only strains surgical capacity but also erodes trust in implant durability, particularly among younger patients seeking long-term solutions.

Geographic Disparities in Access and Surgical Expertise Limit Equitable Care Delivery

Significant variation exists in hip replacement rates and outcomes across European regions, which reflects disparities in healthcare infrastructure and specialist availability, and in turn affects the expansion of the European hip replacement devices market. Rural areas in countries like Greece and Bulgaria face acute shortages of orthopaedic surgeons, with waiting times exceeding several months for elective joint surgery, as reported by national health ministries. Even in high-volume countries, surgeon experience remains a critical variable. The lack of standardised training pathways across the EU further exacerbates outcome variability. These inequities hinder market homogeneity and restrict the adoption of advanced techniques in underserved regions, thereby creating a fragmented landscape where innovation access is dictated more by geography than clinical need.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Insights

In 2024, the total hip replacement segment led the European hip replacement devices market by accounting for a 64.3% share 2024. The high prevalence of end-stage osteoarthritis and established surgical protocols are fuelling the growth of the total hip replacement segment. Osteoarthritis remains the leading indication for total hip arthroplasty across Europe, with millions of adults affected by the condition, according to research. The disease disproportionately impacts individuals over 6,0, who represent a share of the EU population, as per studies. In countries like Germany and Sweden, total hip replacements account for a notable share of all hip interventions due to the irreversible cartilage loss and functional impairment characteristic of advanced disease. National healthcare systems prioritise this intervention because of its proven long-term outcomes. This clinical reliability, combined with an expanding elderly cohort, ensures sustained dominance of the total hip segment. Furthermore, total hip replacement benefits from decades of procedural refinement and implant standardisation across European orthopaedic institutions. Device manufacturers have aligned their portfolios around modular total systems that offer interchangeability of heads, liners, nd stems, simplifying inventory management for hospitals. Apart from these, national joint registries mandate reporting of total hip outcomes, creating robust real-world evidence that reinforces surgeon confidence. This ecosystem of training data standardisation and regulatory oversight has entrenched total hip replacement as the default surgical solution for hip joint failure across both academic and community settings.

The revision hip replacement segment is anticipated to witness the fastest CAGR of 6.8% from 2025 to 2033 due to the accumulation of aging primary implants nearing the end of their functional lifespan, and because advancements in bone graft substitutes and modular revision systems enhance surgical feasibility. Many hip replacements performed around the start of the 21st century are reaching the age where they commonly require replacement. This period is typically when standard artificial hip implants reach the end of their expected functional life. As per sources, the likelihood of needing corrective surgery rises significantly after 15 years. The overall risk of an implant failing increases as it gets closer to 20 years old. In various nations, including Germany, the total quantity of operations to repair or replace older hip implants is growing. The incidence of these revision procedures has shown a pattern of year-over-year increase. This trend is amplified by Europe’s early adoption of joint replacement technology, which means a larger base of legacy implants requires intervention. Revisions are inherently more complex, requiring specialised augments sleeves and bone graft substitutes which drive higher device utilisation per case. The need for revision surgeries will continue to escalate as the large demographic group of initial implant recipients reaches their eighth and ninth decades, which provides structural support for this segment's accelerated growth. Recent innovations in revision-specific implants have significantly improved outcomes in complex cases. Porous tantalum augments and 3D printed titanium cones enable stable fixation even in severe acetabular bone loss. These systems reduce the need for custom-made implants, which previously entailed weeks of lead time. Besides, the integration of intraoperative navigation and robotic assistance enhances precision in component positioning during revision surgery. These technological enablers have lowered the technical barrier for revision procedures, encouraging broader adoption beyond specialised centres and accelerating market expansion.

By Material Insights

The metal on polyethylene segment remained the prominent segment in the European hip replacement devices market and captured a 52.5% share in 2024. The prominence of the metal on the polyethylene segment is driven by its balance of durability, cost, and clinical familiarity. The introduction of high-cross-linked ultra-high molecular weight polyethylene in the late 1990s dramatically reduced wear rates, making metal on polyethylene the standard of care for elderly patients. This reliability is particularly valued in public healthcare systems where long-term outcomes directly impact budgeting and resource allocation. In countries like Italy and Spain, where cost containment is prioritized, metal on polyethylene implants are selected in most primary cases according to national orthopaedic society surveys. The material combination also offers forgiving tribology in cases of suboptimal cup positioning, a common occurrence in high-volume centres. This combination of safety margin, predictable performance, and affordability ensures its continued dominance across diverse European healthcare settings. Cemented femoral stems remain the preferred fixation method for patients over 70 in Northern and Western Europe due to immediate stability and reduced periprosthetic fracture risk. Metal on polyethylene constructs are optimally suited for this approach as the polyethylene liner can be securely locked into cemented acetabular shells without risk of ceramic fracture. Furthermore, the lower cost of polyethylene components aligns with reimbursement constraints in countries that commend cost-effective bearing surfaces for low-demand patients. This clinical and economic synergy between fixation philosophy and bearing selection reinforces the entrenched position of metal on polyethylene in Europe’s ageing surgical landscape.

The ceramic-on-ceramic segment is likely to experience the fastest CAGR of 7.2% over the forecast period, owing to the demand from younger active patients. Ceramic on ceramic articulations exhibit wear rates below 0.02 millimetres per year, lower than conventional polyethylene. In Switzerland and the Netherlands, a share of hip replacements in patients under 5usesse ceramic bearings. These patients are often employed in physically demanding occupations or maintain active lifestyles, making implant longevity a critical decision factor. This demographic reality fuels a preference for ceramic systems despite their higher initial cost. In addition, early concerns about ceramic brittleness and audible squeaking have been largely addressed through fourth-generation composites such as zirconia toughened alumina and improved manufacturing tolerances. Furthermore, the development of skirted ceramic heads and dual taper adapters has enhanced compatibility with existing stem systems, easing surgeon adoption. These engineering advances have restored confidence in ceramic-on-ceramic bearings, particularly in countries with high private pay segments.

By End User Insights

The hospitals segment dominated the European hip replacement devices market and occupied a substantial share in 2024. Their integrated surgical infrastructure and regulatory compliance capabilities have mainly contributed to the expansion of the hospitals segment. Hip arthroplasty, particularly revision and complex primary cases, requires multidisciplinary support rt including anaesthesia, intensive care, and infection control services that are predominantly available in hospital settings. National health systems in some countries mandate that all joint replacements be conducted in facilities accredited for major orthopaedic surgery. This regulatory framework concentrates volume in hospitals, which also benefit from centralised procurement contracts that streamline implant acquisition. Furthermore, hospitals maintain access to national joint registries enabling mandatory outcome reporting, a requirement that smaller facilities often lack the administrative capacity to fulfil. This institutional advantage ensures hospitals remain the primary site of care for the foreseeable future. Besides, all major European joint registries, including those in the UK, Sweden, and Denmark, are hospital-based based requiring participating centres to submit detailed procedural and implant data. This creates a powerful incentive for hospitals to adopt standardised implant systems that facilitate data entry and benchmarking. Device manufacturers further support this ecosystem by providing hospitals with automated data submission tools and surgeon performance dashboards. The resulting feedback loop enhances clinical governance and drives continuous improvement in surgical outcomes. Such systemic integration is difficult to replicate in outpatient settings, which supports hospitals’ dominant position in the care pathway.

The ambulatory surgical centres segment is on the rise and is expected to be the fastest growing segment in the market by witnessing a CAGR of 9.1% from 2025 to 203,3, fuelled by policy and anpatient-drivenen shifts toward outpatient care. Several European governments have launched explicit policies to shift low-risk hip replacements to outpatient settings. These initiatives are supported by bundled payment models that incentivise shorter lengths of stay. Ambulatory centres benefit from lower overhead costs and streamlined workflows,, enablinsame-dayay discharge for medically optimised patients. Device companies are responding with pre-sterilised single-use instrument sets and simplified implant systems that reduce turnover time between cases, a vital efficiency metric in high-throughput outpatient environments. Patients increasingly favour ambulatory settings due to faster scheduling, lower exposure to nosocomial pathogens, and greater postoperative autonomy. As per sources, many adults under 65 would choose an outpatient centre for hip replacement if clinically eligible. This preference is amplified by heightened awareness of hospital-acquired infections. Ambulatory centres report infection rates below 0.5 percent for joint arthroplasty due to strict patient selection and controlled environments. So, the clinical rationale for outpatient hip replacement continues to strengthen, driving rapid adoption across Western and Northern Europe.

COUNTRY LEVEL ANALYSIS

Germany Hip Replacement Devices Market Analysis

Germany was the top performer in the European hip replacement devices market and accounted for a 24.2% share in 2024. The dominance of the German market is driven by its large elderly population, advanced healthcare infrastructure, and high surgical volume. The country performs a large number of hip replacements annually, as documented by the German Endoprosthesis Register. A further driver is the statutory health insurance system, which provides universal coverage for joint arthroplasty with minimal out-of-pocket costs. Germany also hosts Europe’s largest network of orthopaedic device manufacturers, including subsidiaries of Zimmer Biomet and Smith and Nephew, ensuring rapid technology diffusion. The Federal Joint Committee’s strict implant evaluation process mandates registry reporting for all devices, fostering data-driven selection. Apart from these, the national focus on reducing waiting times sustains high procedural throughput. These structural advantages position Germany as the region’s largest and most influential market.

France Hip Replacement Devices Market Analysis

France followed closely in the European hip replacement devices market and captured a 16.5% share in 2024. The growth of the French market is fuelled by its centralised public healthcare system and high prevalence of osteoarthritis. A significant number of hip replacements were performed in 2024. The country’s dominance stems from its hospital-based surgical model, where all joint procedures occur in public or private not-for-profit facilities accredited under the Haute Autorité de Santé framework. France also leads in robotic-assisted arthroplasty. Furthermore, France’s emphasis on postoperative rehabilitation ensures high functional outcomes, which reinforce patient and surgeon confidence in surgical intervention as a standard care pathway.

United Kingdom Hip Replacement Devices Market Analysis

The UK grew moderately in the European hip replacement devices market, with its comprehensive National Health Service and one of the world’s oldest joint registries. The NHS’s adoption of the Getting It Right First Time programme has standardised implant selection around cost-effective, high-performing devices, reducing variation across trusts. A major driver is the Elective Care Recovery Plan, which targets an increase in hip surgery volume to address pandemic backlogs. The UK also pioneers outpatient hip replacement. Despite Brexit-related regulatory divergence, the Medicines and Healthcare products Regulatory Agency maintains alignment with the EU MDR standards, ensuring continued access to innovative implants. This blend of data-driven governance and system-wide recovery initiatives sustains the UK’s strategic importance.

Italy Hip Replacement Devices Market Analysis

Italy expanded gradually in the European hip replacement devices market, with growth concentrated in the northern regions where healthcare funding and surgical capacity are strongest. The country performed thousands of hip replacements in 2024. A distinguishing factor is the high utilisation of cemented implants, particularly in elderly women who constitute a notable share of recipients. Italy’s regional healthcare model creates variation. Besides, Italy shows a strong preference for metal on polyethylene bearings due to cost constraints under tender-based procurement. This north-south divide and fiscal discipline define Italy’s complex but sizable market dynamics.

Sweden Hip Replacement Devices Market Analysis

Sweden is predicted to grow in the European hip replacement devices market from 2025 to 2033 due to its exceptionally high per capita hip replacement rate and world-leading registry infrastructure. Sweden performs hip replacements at a notable rate in Europe. This intensity stems from a proactive public health approach that prioritises mobility preservation to reduce long-term care dependency. The country’s commitment to real-world evidence and patient-centred outcomes makes it a bellwether for implant performance and surgical innovation across Europe.

COMPETITIVE LANDSCAPE

The European Hip Replacement Devices Market exhibits mature yet dynamic competition characterised by the dominance of three to four multinational corporations and a niche presence of regional innovators. Companies compete not on price but on clinical outcomes, technological sophistication, and integration with evolving care pathways such as ambulatory surgery and robotic assistance. The European regulatory environment under EU MDR imposes high barriers to entry, favouring established players with extensive post-market surveillance capabilities and registry linkages. Competition is further shaped by national healthcare procurement policies that increasingly demand health economic data alongside clinical safety. While product differentiation remains centred on bearing couples' stem geometry and modularity, the strategic edge lies in digital ecosystems, surgeon engagement, and real-world evidence generation. Smaller firms struggle to match the scale of clinical validation and regulatory compliance required, making the market highly consolidated yet intensely innovative at the premium segment level.

KEY MARKET PLAYERS

Companies playing a significant role in the European hip replacement market are

• B. Braun Melsungen AG
• Exactech, Inc.
• DJO Global, Inc.
• Johnson & Johnson
• MicroPort Scientific Corporation
• OMNIlife Science, Inc.
• Smith & Nephew
• Zimmer Biomet Holdings, Inc.
• Stryker Corporation.

TOP LEADING PLAYERS IN THE MARKET

• Zimmer Biomet maintains a significant presence in the European Hip Replacement Devices Market through its comprehensive portfolio of primary and revision hip systems, including the widely used Continuum and Allofit platforms. The company actively supports orthopaedic surgeons with extensive training programmes across Germany, France, and the UK, focusing on robotic-assisted and minimally invasive techniques. The firm also strengthened partnerships with national joint registries to enhance real-world evidence generation, aligning with EU Medical Device Regulation requirements. Its global dominance in orthopaedic data analytics further enables tailored implant recommendations based on patient-specific factors, reinforcing its clinical relevance across diverse European healthcare systems.
• DePuy Synthes, a Johnson and Johnson company, plays a pivotal role in the European Hip Replacement Devices Market with its Corail and Pinnacle hip ssystemswhich are among the most frequently implanted devices across Western Europe. The company integrates its implants with the VELYS Robotic Orthopaedic System, which has been deployed in many hospitals across Germany, the Netherlands, and Sweden. The firm also collaborated with the European Federation of National Associations of Orthopaedics and Traumatology to standardise surgical training modules for anterior approach hip arthroplasty. These initiatives reflect its strategic focus on combining implant innovation with digital surgery and education to deepen clinical integration and support value-based healthcare objectives across the region.
• Smith and Nephew is a key contributor to the European Hip Replacement Devices Market through its differentiated REDAPT Revision System and low-friction EMPOWR Hip portfolio tailored for active patients. The company has invested heavily in outpatient arthroplasty solutions, aligning with the growing trend of ambulatory hip replacement in Denmark and the UK. It also enhanced its digital surgical ecosystem by integrating preoperative planning tools with real-time intraoperative feedback via its CORI Robotics platform, now available in many European centres. Furthermore, the firm expanded its regulatory affairs team in Switzerland to ensure seamless compliance with the EU MDR timeline, further solidifying its commitment to sustainable market access and clinical excellence.

TOP STRATEGIES USED BY THE KEY MARKET PARTICIPANTS

Key players in the European Hip Replacement Devices Market primarily focus on strategic initiatives that align with regulatory, clinical, and economic imperatives across the region. These include robust investment in robotic and digital surgery platforms to enhance procedural precision and support outpatient care models. Companies actively collaborate with national joint registries and academic institutions to generate real-world evidence demonstrating long-term implant performance and cost effectiveness. Continuous innovation in bearing materials and 3D printed porous structures addresses the dual needs of longevity and osseointegration, particularly for younger patients. Apart from these, firms are expanding training academies and surgeon education programmes to standardise implantation techniques and reduce complication rates. Strategic localisation of manufacturing and regulatory operations ensures compliance with the EU Medical Device Regulation while accelerating time to market for next-generation devices across diverse healthcare systems.

MARKET SEGMENTATION

This research report on the europe hip replacement devices market has been segmented and sub-segmented into the following categories.

By product

• Total Procedure
• Fixed
• Mobile-Bearing
• Partial Hip Replacement
• Hip Resurfacing
• Revision Hip Replacement

By Material

• Metal
• Metal on Polyethylene
• Ceramic on Metal
• Ceramic on Polyethylene
• Ceramic on Ceramic

By End-user

• Ambulatory Surgical Centres
• Hospitals
• Orthopedic Clinics

By Country

• United Kingdom
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Rest of Europe